Cognition Therapeutics Plunges 12.42% on $30M Stock Offering

On August 28, 2025, Cognition Therapeutics' stock experienced a significant drop of 12.42% in pre-market trading.

Cognition Therapeutics has recently announced a $30 million registered direct offering of common stock. This offering involves the sale of 14.7 million shares to two new institutional investors, including a prominent global investment manager. The proceeds from this offering will be used to fund the preparation for Phase 3 programs of zervimesine in neurodegenerative disorders, as well as for working capital and general corporate purposes.

The offering is expected to close around August 29, 2025, with Titan Partners Group acting as the sole placement agent. This capital infusion is strategically timed as Cognition prepares to advance zervimesine into Phase 3 clinical trials, the final and typically most expensive stage of drug development before potential FDA submission. The additional working capital strengthens Cognition's negotiating position with potential partners and provides operational flexibility during the critical Phase 3 preparation period.